

MEDIA CONTACT:

Sarah Mordis
SS|PR
(847) 415-9301
smordis@sspr.com

**New Diagnosoft® FLOW Measures Coronary Blood Flow Velocity to Aid in
Diagnosis of Heart Disease**

*Advanced Imaging Technology Uses Phase Contrast MRI to Track Velocity; Provides Detailed
Data in Cases Where ECHO May be Ineffective*

SCMR Annual Session, Phoenix, AZ and Cary, NC (January 21, 2009) – Diagnosoft®, Inc., a pioneer in the development of [advanced MRI analysis software](#) for diagnosing, staging and monitoring cardiovascular disease, today announced the launch of [Diagnosoft FLOW](#), the latest diagnostic cardiac imaging tool that aids in the accurate and timely diagnosis and monitoring of heart-related disorders.

Diagnosoft FLOW uses phase contrast MRI to measure the velocity of blood flow through the heart and major vessels to help physicians identify problems in valve performance, arterial stenosis and other anomalies that can manifest in blood flow irregularities. Because it uses images taken from cardiac MRIs, this advanced flow analysis is ideal for use in patients where traditional transthoracic or transesophageal echocardiogram may not be appropriate due to body size or pre-existing medical conditions.

Company representatives will demonstrate the new Diagnosoft FLOW at 10:30 a.m. on Saturday, January 23 in the Spotlight Theatre during the [Society for Cardiovascular Magnetic Resonance 13th Annual Scientific Sessions](#) at the Sheraton Phoenix Downtown Hotel.

“With the addition of FLOW to our family of products, we’ve expanded the powerful Diagnosoft toolset, giving cardiologists yet another way to get a more complete picture of the patient’s cardiac condition,” said Firas BenAhour, president and CEO of Diagnosoft. “By measuring the velocity of blood flow, physicians can better assess cardiac performance and determine the direct effect that stenosis and scar tissue may have on the valves, pulmonary arteries and other cardiac functions.”

FLOW uses advanced image analysis techniques to automatically segment the vessels and track changes in blood flow velocity over time in up to four regions of the heart. These time-lapse images can help physicians identify valvular regurgitation and measure the progression of arterial stenosis or efforts to reverse it. Data and images from Diagnosoft FLOW can be exported to Microsoft Excel data file or a video file for review.

“The images from FLOW are color coded to indicate different velocity measurements based on the images acquired,” BenAhour said. “Since it uses cardiac MR images, there is absolutely no inconvenience to the patient—the post-processing can be done anywhere, anytime, after the patient has left the facility.”

FLOW is available as part of the Diagnosoft PLUS complete diagnostic imaging platform for cardiac MRI quantification and analysis or as a stand-alone product that is compatible with standard MRI technology

widely used throughout the industry.

For more information, visit Diagnosoft at Booth #209 at the SCMR event January 21-25, or visit www.diagnosoft.com.

About Diagnosoft

Diagnosoft, Inc., based in North Carolina, is a privately held company specializing in image analysis software that assists in the diagnosis, staging and therapeutic monitoring of cardiovascular disease. One of its products, Diagnosoft HARP®, is distinguished as the first FDA 510k-Cleared software designed for the analysis of tagged magnetic resonance images. The company is focused on improving physician workflow, quantifying decision-making, and enhancing research and drug development advances. Company founders Dr. Nael Osman and Dr. Jerry Prince developed HARP technology at Johns Hopkins University (JHU), where they are faculty members. Dr. Matthias Stuber, a company founder who is also on the JHU faculty, brings additional insight and imaging expertise to Diagnosoft. For more information, visit www.diagnosoft.com

#